Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $5.9 million.

  • NewAmsterdam Pharma Co N.V's Cash from Financing Activities rose 10058.62% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $472.4 million, marking a year-over-year increase of 132.64%. This contributed to the annual value of $659.5 million for FY2024, which is 7300.21% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Cash from Financing Activities of $5.9 million as of Q3 2025, which was up 72.03% from $3.4 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Cash from Financing Activities high stood at $456.6 million for Q4 2024, and its period low was $58,000 during Q3 2024.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Cash from Financing Activities averaged around $68.4 million, with its median value being $5.3 million (2024).
  • Data for NewAmsterdam Pharma Co N.V's Cash from Financing Activities shows a peak YoY increase of 10,058.62% (in 2025) and a maximum YoY decrease of 96.71% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Cash from Financing Activities stood at $186,000 in 2023, then tumbled by 68.82% to $456.6 million in 2024, then skyrocketed by 10,058.62% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $3.4 million for Q2 2025, and $6.5 million during Q1 2025.